In This Section

What Does Sex Have to Do With It? Implications for Pharmacotherapy

Monday April 08, 2019

2:00 pm - 3:30 pm Eastern Time (ET)

Room W206 A


Chair :

Carrie Northcott
Pfizer Inc.

Susan Wood
Univ of South Carolina Sch of Med

Despite recognition of significant sex differences in susceptibility to stress related disorders such as drug abuse, depression and anxiety, the majority of animal models historically study only male populations. Moreover, the majority of preclinical and clinical studies are not designed to assess sex differences in therapeutic efficacy. Thus there is a lack of understanding of sex-biased mechanisms in the pathogenesis of these disorders, making strategies for sex specific pharmacotherapy unclear. This symposium focuses on studies involving sex differences in pharmacotherapy from clinical to preclinical models and spans layers of analysis from physiology to behavior.


Carrie Northcott - Pfizer Inc.

The Significance of Sex: Sex Differences in Drug Development

Brian Trainor - University of California Davis

Sex Specific Effects of Oxytocin in the Bed Nucleus of the Stria Terminalis on Social Anxiety

Susan Wood - Univ of South Carolina Sch of Med

Sex Differences in Anti-inflammatory Therapies to Increase Resilience to Social Stress

Michael Nader - Wake Forest Sch of Med

Effects of Social Rank and Sex on Cocaine Self-Administration in Monkey Models of Drug Abuse

Last Updated: August 15, 2019
Key Dates
April 6

ASPET Business Meeting and Awards Presentation

April 6-9

ASPET Annual Meeting at EB 2019